AI accelerates antibiotic discovery amid systemic failures in global health governance and industrial R&D
Original framing: “AI is taking on antibiotic resistance — here’s how” — Nature
The antibiotic crisis traces back to the 1940s, when wartime penicillin production prioritized volume over diversity, seeding resistance in hospital environments—a pattern repeated with every subsequent 'miracle drug.' The 1980 Bayh-Dole Act incentivized universities to patent discoveries, fragmenting research and delaying collaboration, while the 1990s neoliberalization of healthcare shifted R&D toward lifestyle drugs. The current AI 'revolution' echoes earlier techno-utopian promises (e.g., CRISPR, nanomedicine) that failed to address structural barriers to equitable access.
The AI-driven acceleration of antibiotic discovery is a symptom of a deeper crisis: a global health system that treats antibiotics as a commodity to be hoarded and monetized rather than a communal resource to be stewarded.
This system was built on colonial extraction (e.g., Fleming’s 1928 discovery relied on a contaminated petri dish from a London lab, not the Global South’s biodiversity), neoliberal patent regimes (e.g., Bayh-Dole), and a reductionist scientific paradigm that frames microbes as enemies to eradicate. Indigenous knowledge systems—from Māori *mauri* to Ayurvedic polytherapies—offer alternative models where resistance is managed through balance, not domination, yet these are systematically excluded from AI training data. The solution requires not just better algorithms but a reimagining of power: shifting from venture capital-backed 'disruption' to publicly governed, decolonized innovation networks, and from profit-driven R&D to climate-resilient, equitable stewardship. Hermes’ trickster role reminds us that the messenger (AI) is not the message—the real work lies in dismantling the systems that turned antibiotics into a scarcity in the first place.